Determining the neuroprotective effects of dextromethorphan in lipopolysaccharide‑stimulated BV2 microglia.

Wenjing Cheng,Yunhong Li,Xiaolin Hou,Bin Bai,Fan Li,Feijia Ding,Jiao Ma,Nan Zhang,Ying Shen,Yin Wang
DOI: https://doi.org/10.3892/mmr.2014.2794
IF: 3.423
2015-01-01
Molecular Medicine Reports
Abstract:Microglial activation has been recognized as being vital in the pathogenesis of several neurodegenerative disorders. Therefore, the identification of therapeutic drugs to prevent microglial activation and thus protect against inflammation-mediated neuronal injury, is required. In the present study, dextromethorphan (DM), a compound widely used in antitussive remedies that has been demonstrated to possess neuroprotective effects, was shown to reduce proinflammatory mediator production in lipopolysaccharide (LPS)-stimulated BV2 mouse microglial cells. Western blot analysis revealed that DM markedly suppressed the activation of nuclear factor-kappa B (NF kappa B), caspase-3 signaling and the expression of another inflammation-inducing factor, heat shock protein 60 (HSP60) and heat shock factor-1, induced by LPS in BV2 cells. Results from ELISA assay demonstrated that DM reduced the release of HSP60, nitric oxide (NO), inducible NO synthase, tumor necrosis factor-alpha, interleukin (IL)-1 beta and IL-6 induced by LPS in BV2 microglia. These results were confirmed by immunofluorescence, suggesting that DM may exert a neuroprotective and anti-inflammatory effect by inhibiting microglial activation through the HSP60-NF kappa B signaling pathway. Therefore, DM may offer substantial therapeutic benefits in the treatment of neurodegenerative diseases that are accompanied by microglial activation.
What problem does this paper attempt to address?